VITA 34 AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
Metrics to compare | V3VGn | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipV3VGnPeersSector | |
---|---|---|---|---|
P/E Ratio | 30.0x | 1.5x | −0.6x | |
PEG Ratio | 0.28 | 0.02 | 0.00 | |
Price/Book | 3.2x | 0.9x | 2.6x | |
Price / LTM Sales | 1.0x | 0.3x | 3.2x | |
Upside (Analyst Target) | 40.6% | 69.2% | 45.4% | |
Fair Value Upside | Unlock | 24.1% | 7.7% | Unlock |